- Home
- Publications
- Publication Search
- Publication Details
Title
Safety considerations when treating myelofibrosis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 15, Issue 9, Pages 1185-1192
Publisher
Informa UK Limited
Online
2016-05-17
DOI
10.1080/14740338.2016.1185414
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
- (2015) N. Kroger et al. BLOOD
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
- (2015) Clodagh Keohane et al. BRITISH JOURNAL OF HAEMATOLOGY
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
- (2015) Adam J. Mead et al. BRITISH JOURNAL OF HAEMATOLOGY
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
- (2015) Massimo Breccia et al. Expert Review of Hematology
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- HMGB1 takes a "Toll" in sickle cell disease
- (2014) K. Gupta BLOOD
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
- (2014) A. Tefferi et al. BLOOD
- Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
- (2014) P. Guglielmelli et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- How I treat myelofibrosis
- (2014) F. Cervantes BLOOD
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
- (2014) John T. Reilly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis
- (2014) Marina Kremyanskaya et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
- (2014) A Pardanani et al. LEUKEMIA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Scouting out the neighborhood in AIDS-related lymphoma
- (2013) K. Dunleavy et al. BLOOD
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment
- (2013) J. Gotlib et al. BLOOD
- Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
- (2013) N Jaekel et al. BONE MARROW TRANSPLANTATION
- Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
- (2013) Jean-Christophe Ianotto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Guideline for the diagnosis and management of myelofibrosis
- (2012) John T. Reilly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
- (2011) A. Tefferi et al. BLOOD
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- The renaissance of interferon therapy for the treatment of myeloid malignancies
- (2011) J.-J. Kiladjian et al. BLOOD
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens
- (2010) Prakash Thapaliya et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- Guideline for investigation and management of adults and children presenting with a thrombocytosis
- (2010) Claire N. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*
- (2010) Eva Löfvenberg et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
- (2008) J-J Kiladjian et al. LEUKEMIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started